Clinical inertia in CKD - What is the rationale for SGLT2i?
Subtitling in English, German, Italian, Spanish and French
Janaka Karalliedde gives an overview of trials and guidelines that provide evidence for using SGLT2 inhibitors to improve outcomes in patients with CKD.
Video navigation menu
- CKD is underdiagnosed in T2DM 01:53
- Kidney outcomes in SGLT2i CV outcome trials 03:37
- Cardiac benefits of SGLT2i in patients with CKD 05:31
- Reno-protective effects of SGLT2i in people with T2DM and HFrEF 06:18
- Diabetes guidelines and KDIGO guidelines 07:57
- Conclusions 10:49
What is true about the outcomes of the EMPA-REG OUTCOME trial?
- A. SGLT2i empagliflozin reduced kidney outcomes (evaluated as secondary outcomes) by 26%
- B. Empagliflozin reduced time to CV death by 29% in patients with diabetes and prevalent kidney disease
- C. The trial showed that empagliflozin has cardioprotective effects, but no reno-protective effects
This lecture by Janaka Karalliedde was part of the EBAC-accredited symposium "SGLT2i in CKD: How to overcome clinical inertia?" held during the virtual ERA EDTA 2021 congress.
Janaka Karalliedde MD, PhD is a clinical senior lecturer in the School of Cardiovascular Medicine & Sciences at King's College London, and a consultant in diabetes, endocrinology and internal medicine at Guy’s and St Thomas’ Hospital London.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by an unrestricted educational grant from Boehringer Ingelheim/Lilly.